Baylor University Medical Center Proceedings October 2017 - 449

combination chemotherapy (14). Furthermore, expression of
P-glycoprotein (an active drug-export mechanism) on NK/Tcell lymphoma cells confers multidrug resistance (15), so regimens such as cyclophosphamide, doxorubicin, vincristine, and
prednisolone have largely been replaced with methotrexate- and
ifosfamide-containing regimens (16). L-asparaginase is another
crucial component of the chemotherapeutic regimen, and phase
II studies of dexamethasone, methotrexate, ifosfamide, etoposide, and L-asparaginase (SMILE) therapy have shown 1-year
overall survival and progression-free survival rates of 45% and
45%, respectively (17). This patient was treated with GELOX,
which in one prospective study showed a 2-year overall survival
rate of 86% and a progression-free survival rate of 86%, with a
local relapse rate of 15% and systemic relapse rate of 11% (18).
It is important to consider the diagnosis of NK/T-cell lymphoma in patients complaining of orbital swelling, especially
those with concomitant ﬁndings of ocular inﬂammation or
other systemic complaints. Orbital biopsy should be considered
in cases of chronic uveitis with nondiagnostic vitreous biopsy
and orbital imaging ﬁndings. When diagnosed early, treatment
with radio- and chemotherapy can be eﬀective for regional sinoorbital NK/T-cell lymphoma.

10.

11.

12.

13.
14.
15.

1.
2.

3.
4.

Choi KH, Lee SJ, Suh YL, Kim YD. Nasal-type natural killer/T-cell
lymphoma of the orbit. J Korean Ophthalmol Soc 2004;45:2145-2150.
Cimino L, Chan C-C, Shen D, Masini L, Ilariucci F, Masetti M, Asioli S,
Sartori A, Cappuccini L. Ocular involvement in nasal natural killer T-cell
lymphoma. Int Ophthalmol 2009;29(4):275-279.
Aozasa K, Zaki MA. Epidemiology and pathogenesis of nasal NK/T-cell
lymphoma: a mini-review. Sci World J 2011;11:422-428.
Coupland SE, Foss HD, Assaf C, Auw-Haedrich C, Anastassiou G,
Anagnostopoulos I, Hummel M, Karesh JW, Lee WR, Stein H. T-cell
and T/natural killer-cell lymphomas involving ocular and ocular adnexal
tissues: a clinicopathologic, immunohistochemical, and molecular study
of seven cases. Ophthalmology 1999;106(11):2109-2120.
Hon C, Kwok AK, Shek TW, Chim JC, Au WY. Vision-threatening complications of nasal T/NK lymphoma. Am J Ophthalmol 2002;134(3):406-
410.

October 2017

16.
17.

18.

Mo ZY, Wang P, Yang HW, Li WB, Liang QL. Esophageal metastasis
secondary to extranodal nasal-type natural killer/T-cell lymphoma: a case
report. Mol Clin Oncol 2016;5(1):207-209.
Sandner A, Helmbold P, Winkler M, Gattenlöhner S, Müller-Hermelink
H-K, Holzhausen HJ. Cutaneous dissemination of nasal NK/T-cell
lymphoma in a young girl. Clin Exp Dermatol 2008;33(5):615-618.
Romero-Guadarrama MB, Aguilar-Martínez E. Extranodal nasal NK/
T-cell lymphoma with dissemination to the central nervous system: a case
report. Acta Cytol 2010;54(5 Suppl):993-997.
Kim JW, An JH. Extranodal natural killer/T-cell lymphoma, nasal
type, of the orbit mimicking recurrent orbital cellulitis. J Craniofac Surg
2014;25(2):509-511.
Ely A, Evans J, Sundstrom JM, Malysz J, Specht CS, Wilkinson M. Orbital
involvement in extranodal natural killer T cell lymphoma: an atypical case
presentation and review of the literature. Orbit 2012;31(4):267-269.
Abe RY, Pinto RDP, Bonﬁtto JFL, Lira RPC, Arieta CEL. Ocular masquerade syndrome associated with extranodal nasal natural killer/T-cell
lymphoma: case report. Arq Bras Oftalmol 2012;75(6):430-432.
Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS, Ngan RK.
Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113
patients. J Clin Oncol 1998;16(1):70-77.
Au WY. Current management of nasal NK/T-cell lymphoma. Oncology
(Williston Park) 2010;24(4):352-328.
Tse E, Kwong YL. Diagnosis and management of extranodal NK/T cell
lymphoma nasal type. Expert Rev Hematol 2016;9(9):861-871.
Yamaguchi M, Kita K, Miwa H, Mishii K, Oka K, Ohno T, Shirakawa S,
Fukumoto M. Frequent expression of P-glycoprotein/MDR1 by nasal
T-cell lymphoma cells. Cancer 1995;76(11):2351-2356.
Tse E, Kwong YL. Management of advanced NK/T-cell lymphoma. Curr
Hematol Malig Rep 2014;9(3):233-242.
Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C,
Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H,
Hyo R, Nakamura S, Oshimi K, Suzuki R. Phase II study of SMILE
chemotherapy for newly diagnosed stage IV, relapsed, or refractory
extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NKCell Tumor Study Group study. J Clin Oncol 2011;29(33):4410-4416.
Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, Xia ZJ. First-line
combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX)
followed by involved-ﬁeld radiation therapy for patients with stage IE/
IIE extranodal natural killer/T-cell lymphoma. Cancer 2013;119(2):
348-355.

Natural killer/T-cell lymphoma invading the orbit and globe

449

Table of Contents for the Digital Edition of Baylor University Medical Center Proceedings October 2017